Author Archives: Nick Taylor

Nick Paul Taylor is an experienced life sciences journalist and biopharma writer with a background in biology and healthcare innovation. Over the past 15 years, he has covered key developments in pharmaceutical research, biotechnology, drug regulation, and medical technology, writing for leading industry publications. Nick’s reporting focuses on translating complex clinical data, FDA updates, and biotech trends into accessible insights for professionals across the pharma and medtech sectors. Follow Nick for expert analysis on biopharma pipelines, regulatory news, and emerging healthcare technologies.
  • Why isn’t Cardarine (GW501516) available?

    The truth about why we don’t stock GW501516 – and why you should be cautious if you see it elsewhere. What is Cardarine? Cardarine (GW501516) is a PPARδ receptor agonist originally developed for metabolic and cardiovascular research. It was never approved for human use and was discontinued during preclinical trials. So why isn’t it sold …

    More
  • How to find the best company for SARMS in the UK

    Let’s be honest: The SARMs market is flooded with bold claims, sketchy suppliers, and zero accountability. So how do you cut through the noise and find a brand you can actually trust? Here’s a proven step-by-step approach: 1. Start With UK-Based Companies If you’re in the UK, go local.Why? Faster shipping, no customs headaches, and …

    More
  • SARMs Law Update: Where Are We in 2025?

    Are SARMs legal in 2025? The short answer: not really. In the U.S., the FDA calls them ‘unapproved drugs’ and is prosecuting companies that sell them as supplements. In the UK, regulators classify them as ‘novel foods,’ which means they can’t be sold for human consumption either. You might still see them marketed online, often …

    More
  • Checking the research on MK-677

    To save you reading all the small print, we’ve reviewed and summarised the research about MK677 Study 1: Nass R, et al. (2008) Title: Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trialLink: PubMed Summary This randomized, double-blind, placebo-controlled trial evaluated the long-term effects (12 …

    More
  • MK677 Ibutamoren Side Effects

    What’s the Deal with MK-677, Really? MK-677 is what scientists call a ghrelin receptor agonist and a growth hormone secretagogue. In simpler terms, it basically tricks your body into thinking you’re hungry, which then sparks a release of growth hormone (GH) and IGF-1. Sounds kind of amazing, right? Like just taking a pill and kicking …

    More
  • Your guide to MK-677

    Meet MK-677, also known as Ibutamoren. It’s not a SARM. Let’s get that out of the way early. It merely loiters in the same online forums, gets mistaken for one due to guilt by association, and is occasionally found wearing a hoodie that says “anabolic.” But scientifically? It’s a growth hormone secretagogue. A fancy term …

    More
  • Are SARMs Legal in UK? A Solicitors View

    Selective Androgen Receptor Modulators (SARMs UK) have become a major focus for legal and regulatory discussions, especially concerning their use in bodybuilding, performance enhancement, and experimental medical treatments. Promoted for their ability to boost muscle growth with fewer side effects than anabolic steroids, SARMs occupy a legal gray area, with their status varying widely across …

    More
Hurry while stocks last! Use code PAYDAY15 at checkout to get 15% off sitewide. Valid for
Updating
  • No products in the cart.